Quidel Stock Price, News & Analysis

QuidelOrtho (NASDAQ: QDEL) has launched the QUICKVUE Influenza + SARS Test, a professional-use diagnostic tool that simultaneously detects and differentiates between influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample. The CLIA-waived, 510(k)-cleared test delivers results in as fast as 10 minutes.

The test is designed for use in physician office laboratories, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs. Key features include triple detection capability, fast results, professional use designation, efficient workflow with easy-to-collect nasal swabs, and cost-effective visual combo testing. The product is available in the United States through QuidelOrtho's existing distribution channels but is not intended for in-home use.

QuidelOrtho (NASDAQ: QDEL), a global provider of in vitro diagnostic technologies, announced its participation in the upcoming Baird 2025 Global Healthcare Conference. The company's management team will engage in a fireside chat on September 10, 2025, at 3:10 p.m. ET.

Investors and interested parties can access the live webcast and replay through QuidelOrtho's investor relations website. The company specializes in diagnostic solutions for point-of-care settings, clinical laboratories, and transfusion medicine.

QuidelOrtho (NASDAQ: QDEL) has successfully completed a comprehensive debt refinancing initiative to strengthen its capital structure. The refinancing package includes a $1.15 billion 5-year senior secured Term Loan A, a $100 million delayed draw Term Loan A, a $1.45 billion 7-year senior secured Term Loan B, and a $700 million revolving credit facility.

The restructuring extends debt maturities and reduces required amortization payments, providing enhanced financial flexibility. CFO Joseph Busky emphasized that reducing total debt and net debt leverage remains the company's primary capital allocation priority.

QuidelOrtho (NASDAQ: QDEL) released the 50th episode of its Science Bytes podcast featuring Dr. Jonathan Temte from the University of Wisconsin-Madison discussing respiratory virus prevention in schools. The episode focuses on seasonal health challenges including influenza, RSV, COVID-19, and vaccine-preventable diseases.

Dr. Temte emphasizes three key strategies: early detection through rapid diagnostics for targeted treatment, monitoring absenteeism data to predict outbreaks, and implementing preventive measures to reduce disease transmission in schools and homes. The podcast is available on major streaming platforms and QuidelOrtho's website.

QuidelOrtho (NASDAQ: QDEL) has appointed Erich Wolff as Executive Vice President of Strategy & Corporate Development, reporting to CEO Brian Blaser. Wolff brings over 20 years of leadership experience in healthcare, diagnostics, and MedTech sectors.

Previously serving as Buyouts Lead at Partners Group ($174B AUM), Wolff held senior roles at BD and Medtronic. At Medtronic, he revitalized the global diabetes business and managed corporate development for $11.5B neurosciences and diabetes units. At BD, he led key transactions including the embecta spinoff and $1.5B Parata Systems acquisition.

QuidelOrtho (NYSE:QDEL) has launched its Certified Analyzer Program, aimed at expanding access to diagnostic testing in rural and community hospitals across the United States. The initiative focuses on healthcare facilities with fewer than 100 beds, offering certified VITROS™ analyzers at reduced costs.

The program features certified VITROS XT 7600, 5600 Integrated Systems, and VITROS 3600 Immunodiagnostic System. Each analyzer undergoes a rigorous certification process including over 140 system checks, hardware maintenance, and performance testing at QuidelOrtho's Rochester facility. The certified analyzers come with a 12-month warranty on service and support.

QuidelOrtho (NASDAQ: QDEL) reported Q2 2025 financial results with total revenue of $614 million. The company's Labs revenue grew 4% as reported and 5% in constant currency, while Immunohematology revenue increased by 4% as reported. However, respiratory revenue declined 20% to $47 million due to lower COVID-19 revenue.

The company reported a GAAP net loss margin of (42%) and GAAP diluted loss per share of $3.77. Adjusted EBITDA margin improved by 330 basis points to 17%, with adjusted diluted EPS of $0.12. QuidelOrtho achieved its targeted $100 million annualized cost savings and reiterated its full-year 2025 guidance with expected revenues of $2.60-$2.81 billion.

QuidelOrtho (NYSE:QDEL) has secured three prestigious awards in the 2025 IMV ServiceTrak™ Awards, demonstrating excellence in customer satisfaction. The company received awards for Best Overall System Performance in both Chemistry and Integrated Systems categories, along with Best Overall Service for Integrated Systems.

The company achieved #1 rankings in multiple categories including Overall Net Promoter Score, Manufacturer Performance, Service Engineer Performance, and Training Performance. Notably, QuidelOrtho recorded a 17-point increase in NPS, marking the largest gain in the category.

QuidelOrtho (NYSE:QDEL) released Episode 49 of its Science Bytes podcast, focusing on the critical role of rapid diagnostic testing in drug overdose cases. The episode features Vonda McAllister, Director of Global Product Management, discussing urgent challenges in emergency departments amid rising drug complexities.

The podcast highlights several key issues including the limitations of Narcan, the increasing prevalence of synthetic drugs like fentanyl and xylazine, and the implementation of California's Tyler's Law mandating fentanyl testing. The discussion emphasizes how rapid diagnostic testing can improve clinical decision-making and potentially save lives in emergency care settings.